PEN-866 is a Small Molecule owned by Tarveda Therapeutics, and is involved in 1 clinical trial, which is ongoing.
PEN-866 works by delivering SN-38 to tumor cells. SN-38 is an active metabolite of irinotecan which acts by blocking an enzyme, called topoisomerase I. Blocking of this enzymes leads to DNA tang which prevent cells from dividing. Hsp90 is up-regulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of client proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors. By delivery of the cytotoxic payload to the cancer cells, it causes regressions of tumors.
The revenue for PEN-866 is expected to reach a total of $134m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PEN-866 NPV Report.
PEN-866 was originated by Synta Pharmaceuticals and is currently owned by Tarveda Therapeutics. SciClone Pharmaceuticals Holdings is the other company associated in development or marketing of PEN-866.
PEN-866 is under development for the treatment of small cell lung cancer, rhabdomyosarcoma, triple negative breast cancer, colorectal cancer, Ewing sarcoma, gastric adenocarcinoma, ovarian cancer and pancreatic adenocarcinoma and liposarcoma. The drug candidate is a Hsp90 inhibitor linked to SN-38 via a cleavable chemical linker. SN-38 acts by targeting topoisomerase I. The drug candidate is developed based on Hsp90-inhibitor drug conjugates (HDCs) platform technology. It is administered through intravenous route. It was also under development for the treatment of non-small cell lung cancer, bladder cancer and melanoma.
SciClone Pharmaceuticals Holdings Overview
SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.
The company reported revenues of (Renminbi) CNY2,518.5 million for the fiscal year ended December 2021 (FY2021), an increase of 31.3% over FY2020. In FY2021, the company’s operating margin was 42%, compared to an operating margin of 43.5% in FY2020. In FY2021, the company recorded a net margin of 36.7%, compared to a net margin of 39.3% in FY2020.
Quick View – PEN-866
|Highest Development Stage|